Imatinib
- Generic Name
- Imatinib
- Brand Names
- Gleevec, Glivec, Imatinib Teva, Imatinib Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C29H31N7O
- CAS Number
- 152459-95-5
- Unique Ingredient Identifier
- BKJ8M8G5HI
- Background
Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated with a daily dosage of 300 mg or more and ...
- Indication
Imatinib is indicated for the treatment of adult and pediatric chronic myeloid leukemia with Philadelphia chromosome mutation (Ph+) in blast crisis, accelerated phase, or chronic phase after IFN-alpha therapy failure.Additionally, imatinib is also indicated to treat adult and pediatric Ph+ acute lymphoblastic leukemia, adult myelodysplastic/myeloproliferativ...
- Associated Conditions
- Accelerated Phase Chronic Myelogenous Leukemia (CML), Aggressive Systemic Mastocytosis, Chordomas, Chronic Eosinophilic Leukemia, FIP1L1-PDGFRα fusion kinase status unknown Chronic eosinophilic leukemia, FIP1L1-PDGFRα fusion kinase status unknown Hypereosinophilic syndrome, Gastrointestinal Stromal Tumor (GIST), Hypereosinophilic Syndrome (HES), Metastatic Gastrointestinal Stromal Tumor (GIST), Metastatic Melanoma, Myelodysplastic Syndrome, Myeloproliferative Disorders (MPD), Refractory Acute Lymphoblastic Leukemia (ALL), Blast phase Chronic myeloid leukemia, CKit mutational status unknown Aggressive systemic mastocytosis, Metastatic Dermatofibrosarcoma protuberans, Newly diagnosed Acute Lymphoblastic Leukaemia, Newly diagnosed, chronic phase Chronic myeloid leukemia, Recurrent Dermatofibrosarcoma protuberans, Refractory, chronic phase Chronic myeloid leukemia, Unresectable Gastrointestinal stromal tumor
- Associated Therapies
- -
Study of Imatinib-Combined Chemotherapy for BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL)
- First Posted Date
- 2005-08-15
- Last Posted Date
- 2008-11-14
- Lead Sponsor
- Japan Adult Leukemia Study Group
- Target Recruit Count
- 100
- Registration Number
- NCT00130195
- Locations
- 🇯🇵
Department of Hematology, Nagoya University Graduate School of Medicine, Nagoya, Japan
Study Comparing 12 Months Versus 36 Months of Imatinib in the Treatment of Gastrointestinal Stromal Tumor (GIST)
- First Posted Date
- 2005-07-01
- Last Posted Date
- 2011-12-30
- Lead Sponsor
- Scandinavian Sarcoma Group
- Target Recruit Count
- 400
- Registration Number
- NCT00116935
- Locations
- 🇸🇪
Scandinavian Sarcoma Group, Southern Swedish Regional Tumour Registry, Lund University Hospital, Lund, Sweden
Trial Evaluating Gleevec in Patients With Anaplastic Thyroid Carcinoma
- First Posted Date
- 2005-06-24
- Last Posted Date
- 2014-04-21
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 11
- Registration Number
- NCT00115739
- Locations
- 🇺🇸
University of Michigan Cancer Center, Ann Arbor, Michigan, United States
Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2005-02-16
- Last Posted Date
- 2010-08-10
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 150
- Registration Number
- NCT00103844
- Locations
- 🇬🇧
Local Institution, Newcastle, Tyne and Wear, United Kingdom
Gleevec Trial in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
- Conditions
- First Posted Date
- 2004-04-29
- Last Posted Date
- 2009-11-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 112
- Registration Number
- NCT00081926
- Locations
- 🇺🇸
Novartis RIGHT Trial Hotline, East Hanover, New Jersey, United States
Imatinib (Gleevec(Registered Trademark)) to Treat Chronic Myelomonocytic Leukemia and Atypical Chronic Myelogenous Leukemia
- Conditions
- First Posted Date
- 2004-03-10
- Last Posted Date
- 2017-07-02
- Target Recruit Count
- 7
- Registration Number
- NCT00079313
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukemia (CML)
- Conditions
- Interventions
- First Posted Date
- 2003-02-07
- Last Posted Date
- 2016-05-11
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 94
- Registration Number
- NCT00050531
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Therapy of Early Chronic Phase CML With Gleevec
- First Posted Date
- 2002-11-06
- Last Posted Date
- 2016-01-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT00048672
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2002-08-26
- Last Posted Date
- 2024-12-19
- Target Recruit Count
- 60
- Registration Number
- NCT00044304
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Therapy of Early Chronic Phase CML With Higher-Dose Gleevec, Alpha Interferon, and Low-Dose Ara-C
- First Posted Date
- 2002-06-04
- Last Posted Date
- 2018-10-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 117
- Registration Number
- NCT00038649
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.